Five-Year Survival and Durable Remission with Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Insights from the TRANSCEND NHL 001 Study

Lisocabtagene maraleucel (liso-cel) yields a median overall survival of 27.5 months in relapsed or refractory large B-cell lymphoma (R/R LBCL) patients.
Estimated five-year overall survival (OS) reaches 38% in efficacy-evaluable patients, supporting durable responses.
Disease-specific survival (DSS) estimates at five years show even higher rates, suggesting sustained control of lymphoma-related mortality.
Long-term follow-up reveals no new safety concerns, with low rates of late severe infections and second primary malignancies, underscoring a favorable safety profile.